Preserving Lean Mass on GLP-1 Drugs: What the Resistance Training and Protein Evidence Actually Supports

DXA data from major GLP-1 trials consistently shows 25–45% of weight lost is lean tissue — here's what the resistance training and protein evidence actually supports for mitigating that.

The Starting Point: How Much Lean Mass Are We Talking About?

DXA substudies from major GLP-1 trials consistently show that a meaningful share of weight lost on semaglutide or tirzepatide is lean tissue rather than fat — roughly 25–45% of total weight lost, depending on the drug, dose, and the study population. Semaglutide appears to sit toward the higher end of that range. "Lean mass" in this context includes muscle, water, and organ tissue; trials don't always isolate skeletal muscle specifically, which is worth keeping in mind when interpreting the figures.

These numbers are the reason resistance training and adequate protein have become standard companion recommendations alongside GLP-1 therapy, not optional extras.

Why Lean Mass Loss Happens During Any Caloric Deficit

This is not a GLP-1-specific toxicity. It's a general consequence of sustained caloric deficit regardless of method: the body doesn't perfectly discriminate between mobilising stored fat and breaking down muscle protein for energy. The larger and faster the deficit, the larger the share of lean mass typically at risk.

What makes GLP-1 drugs distinct is the scale and duration of the deficit they produce. Appetite suppression is unusually effective, creating deficits that are larger and more sustained than most dietary interventions achieve. That's the mechanism behind the impressive scale-weight results — and it's the same mechanism that makes the lean-mass-loss proportion show up so prominently in trial data.

The Mechanism: Why Exercise and Protein Work as a Paired Intervention

Without a training stimulus, the body has little physiological reason to preserve muscle during a large energy deficit. Resistance training provides a mechanical and hormonal signal that prioritises muscle tissue even while fat is being mobilised — shifting the composition of what's lost rather than stopping loss entirely. This principle is well-established in the broader body-composition literature and is being applied, by extrapolation, to GLP-1 users.

Protein intake is the other half of the equation. Amino acids supply the raw material that the training stimulus needs to actually preserve or rebuild tissue. Higher-protein diets during caloric deficit are consistently associated with better lean mass retention compared to lower-protein deficits of equivalent caloric reduction. The two interventions are interdependent: exercise without adequate protein has less to work with; protein without a training signal has less reason to be directed toward muscle preservation.

The particular challenge with GLP-1 drugs is mechanical: appetite suppression makes it harder to reach adequate protein targets simply because total food volume drops substantially. Protein-forward food choices need to be deliberate rather than assumed from volume alone. Morning appetite suppression — a common GLP-1 effect — can mean early-day protein is the first thing to fall short.

What the Trial Data Shows

One study cited in the source material found that participants in a severe caloric deficit who combined hard resistance training with high protein intake actually gained lean mass while losing fat — reversing the usual trade-off. That result is worth noting, but it should be read in context: much of the protein and resistance training data comes from small, short-duration trials (weeks to months, not years), and study populations have often been male or younger and athletic. Direct applicability to perimenopausal or postmenopausal women — who face concurrent hormone-driven muscle and bone loss — is inferred, not yet directly tested in this context.

One study followed people after stopping GLP-1 medication for one year and found that those who had maintained a structured exercise habit during therapy regained weight more slowly and retained better body composition than those who had relied on medication alone. Longer-term relapse patterns beyond one year are not established.

Source 1 (the MyKine original) does not name specific trials. Source 2 (Dr. Gordon's Substack piece) names results but does not provide trial names or citation details. Neither source names effect sizes with enough precision to report specific numbers here beyond the 25–45% lean-mass-loss range already noted. Per house style, no additional trial names, numbers, or effect sizes have been added.

Evidence Gaps to Be Honest About

The directional case — resistance training plus adequate protein reduces lean mass loss during a GLP-1-driven deficit — is well-supported by general body-composition evidence and biologically plausible. What's thinner:

GLP-1-specific dose-response data. Precise quantitative targets (how much protein, how many training sessions, what volume) specifically studied in GLP-1 users are not yet well-established. Current recommendations are extrapolated from general weight-loss literature.
Population representativeness. Most protein-and-training trials have been conducted in younger, male, or athletic populations. Perimenopausal and postmenopausal women, older adults, and people with high baseline adiposity may respond differently.
Trial duration. Short trial windows (weeks to a few months) may not capture longer-term adaptations or attrition in training habits.
Lean mass measurement. "Lean mass" on DXA captures more than skeletal muscle. Studies that don't isolate skeletal muscle specifically may overstate or mischaracterise the muscle-specific signal.
Individual variation. The proportion of lean vs. fat loss varies by drug, dose, and individual baseline characteristics.

One additional monitoring consideration from the evidence: bone mineral density may decline on GLP-1 therapy alone, and resistance training appears to offer some protective effect that medication does not. For MyKine users tracking biomarkers, BMD is worth adding to the monitoring list, particularly for women in perimenopause or menopause and for anyone on longer-term GLP-1 therapy. The evidence base for this specific claim is not detailed in the source material beyond the observation itself.

A note on protein targets: the 0.6 g per pound of body weight figure cited in one source is a practical starting point, but that assumes normal kidney function. Anyone with renal disease needs clinician-adjusted targets — this is not a general population number in that context.

Practical Takeaway

Lean mass loss on GLP-1 drugs is real and well-documented — roughly 25–45% of total weight lost is lean tissue in trial data, not a myth to dismiss.
Resistance training and adequate protein are the two most evidence-aligned levers for mitigating this; the evidence supports using both together, not either alone.
Protein intake needs to be deliberate, not assumed from total food volume — GLP-1-driven appetite suppression makes it easy to undereat protein even while total calories drop appropriately.
The directional recommendation is well-supported; the precise GLP-1-specific targets are not yet settled — recommendations are extrapolated from general body-composition literature, not derived from large, long-duration GLP-1-specific trials.
For users tracking biomarkers, lean mass (via DXA or similar), strength metrics, and bone mineral density are all relevant to monitor during GLP-1 therapy — scale weight alone doesn't tell the full story.
Post-discontinuation body composition appears better in people who trained during therapy — based on one one-year follow-up study; longer-term data don't yet exist.